Study #2022-0421
A phase 2 multi-cohort, open-label, multi-center clinical study evaluating the efficacy and safety of Disitamab Vedotin (RC48-ADC) alone or in combination with Pembrolizumab in subjects with locally-advanced unresectable or Metastatic Urothelial Carcinoma that expresses HER2
MD Anderson Study Status
Not Accepting
Treatment Agent
disitamab vedotin, pembrolizumab
Description
This study is being done to see if a drug called disitamab vedotin, alone or with pembrolizumab, works to treat HER2 expressing urothelial cancer. It will also test how safe the drug is for participants. Participants will have cancer that has spread in the body near where it started (locally advanced) and cannot be removed (unresectable) or has spread through the body (metastatic). It will also study what side effects happen when participants get the drug. A side effect is anything a drug does to your body besides treating the disease.
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Urothelial Carcinoma
Study phase:
Phase II
Physician name:
Matthew Campbell
Department:
Genitourinary Medical Oncology
For general questions about clinical trials:
1-888-912-0153
Help #EndCancer
Give Now
Donate Blood
Our patients depend on blood and platelet donations.
Shop MD Anderson
Show your support for our mission through branded merchandise.